American Association for Cancer Research
Browse
10559965epi120498-sup-fig3.pdf (78.65 kB)

Supplementary Figure 3 from SOX2 Autoantibodies As Noninvasive Serum Biomarker for Breast Carcinoma

Download (78.65 kB)
journal contribution
posted on 2023-03-31, 14:00 authored by Yu Sun, Rui Zhang, Minjie Wang, Yuan Zhang, Jun Qi, Jinming Li

PDF file, 78K, Supplementary Figure 3: Venn diagrams analysis for the overlapping group of patients positive for SOX2-Abs and serum CA 15-3, CA 125, CEA and TPS.

History

ARTICLE ABSTRACT

Background: A clear association has been established between antibodies to the transcription factor sex-determining region Y (SRY)-box 2 (SOX2) and small cell lung cancer. In light of the pathologic role of SOX2 and its aberrant expression in breast cancer, we measured serum SOX2 autoantibodies (SOX2-Abs) in breast cancer patients.Methods: The presence of SOX2-Abs was determined by an indirect enzyme-linked immunosorbent assay (ELISA) in sera from 282 patients with breast cancer, 78 patients with benign breast disease, and 194 healthy women.Results: SOX2-Abs were more prevalent in patients with breast cancer (18.4%) compared with healthy women (2.6%, P < 0.0001), and patients with benign breast disease (6.4%, P = 0.011). The concentrations of circulating SOX2-Abs were found to discriminate between breast cancer patients and healthy controls (P < 0.001) and between breast cancer patients and those with benign breast disease (P < 0.001). In addition, measurement of SOX2-Abs was more effective than assays of serum tissue polypeptide-specific antigen, carcinoembryonic antigen, carbohydrate antigen (CA) 125, and CA 15-3 in distinguishing between malignant and benign breast disease. In breast cancer patients, the prevalence of SOX2-Abs was associated with a higher tumor grade (P = 0.021) and positive nodal status (P = 0.021).Conclusion: The presence of SOX2-Abs in breast cancer may be of clinical value.Impact: This study provides the first evidence for the presence of circulating SOX2-Abs in breast cancer and shows their potential clinical application. Cancer Epidemiol Biomarkers Prev; 21(11); 2043–7. ©2012 AACR.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC